|
|
Vaccine Detail
|
MUC1-MALP2 (Pam?Cys) Conjugate Vaccines (unglycosylated/Tn/T) |
| Vaccine Information |
- Vaccine Name: MUC1-MALP2 (Pam?Cys) Conjugate Vaccines (unglycosylated/Tn/T)
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: MUC1 (McDonald et al., 2014)
- Immunization Route: subcutaneous injection
- Description: A synthetic self-adjuvanting glycopeptide vaccine comprising MUC1 VNTR glycopeptide antigens covalently conjugated to macrophage activating lipopeptide 2 (MALP2) adjuvant via a triethyleneglycol spacer. Three variants were evaluated: unglycosylated, Tn-perglycosylated (GalNAc-?-Ser/Thr), and T-perglycosylated (Gal(?1-3)GalNAc-?-Ser/Thr) at five sites within the MUC1 VNTR. The MALP2 component (MALP2 peptide-Pam2CysGly) acts as a TLR2/6 agonist enabling direct B-cell activation. Vaccination of C57BL/6 mice induced high-titer class-switched IgG antibodies (IgG1, IgG2b, IgG3) without external adjuvants or helper T-cell epitopes, demonstrating T-cell-independent class switching. The unglycosylated variant exhibited highest antibody titres. Antibodies recognized MUC1 VNTR epitopes including SAPDTRPAP, with Tn-glycosylated variant showing cross-reactivity to unglycosylated and T-glycosylated forms. No cytotoxic T-cell responses were observed. Induced IgG antibodies are potentially capable of mediating ADCC and complement activation, though not functionally tested (McDonald et al., 2014).
|
| Host Response |
|
|
| References |
McDonald et al., 2014: McDonald DM, Wilkinson BL, Corcilius L, Thaysen-Andersen M, Byrne SN, Payne RJ. Synthesis and immunological evaluation of self-adjuvanting MUC1-macrophage activating lipopeptide 2 conjugate vaccine candidates. Chemical communications (Cambridge, England). 2014; 50(71); 10273-10276. [PubMed: 25056269].
|
|
